Breaking Finance News

ValuEngine upgraded Five Prime Therapeutics Inc (NASDAQ:FPRX) to Sell in a statement released earlier today.

Showing a price of $29.52, Five Prime Therapeutics Inc (NASDAQ:FPRX) traded 1.17% higher on the day. With the last stock price close down 44.37% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same period. FPRX has recorded a 50-day average of $38.36 and a two hundred day moving average of $32.42. 283,149 shares of Five Prime Therapeutics Inc exchanged hands, down from an avg. volume of 333,045

ValuEngine has upgraded Five Prime Therapeutics Inc (NASDAQ:FPRX) to Sell in a report released on 6/02/2017.

Performance Chart

Five Prime Therapeutics Inc (NASDAQ:FPRX)

With a market capitalization of $0, Five Prime Therapeutics Inc has 52 week low of $25.97 and a 52 week high of $60.98 .

Also covering Five Prime Therapeutics Inc's target, a total of 6 brokerages have released a report on Five Prime Therapeutics Inc. The 12-month price target is $45.83 with five analysts rating the company a strong buy, 1 broker rating the stock a buy, 0 brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly 0 firms rating the stock a sell.

General Information About Five Prime Therapeutics Inc (NASDAQ:FPRX)

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.